Newly FDA Approved Glasses Can Help Slow Down Your Child's Myopia Progression

Parents familiar with managing their childs nearsightedness know the routine: frequent eye exams, vision checks, and updating prescriptions. A new FDA-approved option now offers a potential way to slow the worsening of myopia rather than just correct it.

Essilor Stellest eyeglass lenses, the newly approved product, have demonstrated a significant reduction in myopia progression over a two-year period. These glasses are now being introduced across the U.S. market.

What Sets These Lenses Apart?

Currently, only one other product exists to slow myopia in children: MiSight contact lenses, which are approved for ages 8 to 12 and are available as daily disposables. Essilor Stellest lenses, on the other hand, can be used by children starting at age 6 and come in eyeglass form, offering an alternative for children who cannot wear contacts or whose parents prefer glasses over disposables.

The FDA explained the mechanism behind these lenses: Essilor Stellest eyeglass lenses feature a 9mm clear central zone surrounded by tiny raised dots, called peripheral lenslets, across the rest of the lens. These lenslets create peripheral light defocus, which may slow myopia progression in children.

Clinical Trials Leading to Approval

The FDAs approval followed a two-year clinical study comparing Essilor Stellest lenses to standard single-vision lenses. While minor visual effects such as blurriness and halos were reported, no serious adverse effects were observed. The study confirmed that the lenses significantly reduced changes in eye shape that typically contribute to worsening myopia.

Experts note that myopia often progresses during childhood as the eyes grow, stabilizing in early adulthood. Prior to Essilor Stellest, only MiSight contact lenses were available to slow myopia progression for a limited age range.

Insurance and Cost Considerations

Insurance coverage for Essilor Stellest lenses has not yet been clearly established. However, major vision insurance plans are expected to include them in the future. Parents interested in these glasses should contact their insurer to check current coverage or prepare to cover the cost themselves, which is approximately $450 per pair.

Analysis: Essilor Stellest Lenses and Their Potential Impact on Myopia Management

The introduction of Essilor Stellest eyeglass lenses provides a significant advancement in the fight against childhood myopia. Unlike traditional corrective lenses that simply address the symptoms of myopia, these new lenses offer a potential solution to slow its progression. With approval from the FDA, Essilor Stellest lenses demonstrate their effectiveness over a two-year period in reducing the worsening of myopia in children, a notable development for both parents and optometrists.

One key factor that sets Essilor Stellest lenses apart from existing options is their design and functionality. Unlike MiSight contact lenses, which are limited to children ages 8 to 12, Essilor Stellest lenses can be used by children as young as 6 years old. Additionally, they provide a much-needed option for children who are unable to wear contact lenses or whose parents prefer eyeglasses over daily disposables. The peripheral lenslets incorporated into the lenses create defocus that can effectively slow myopia progression, offering a scientifically-backed solution to a growing concern.

While the lenses' mechanism of action shows promise, insurance coverage remains a potential hurdle. With no clear information on coverage yet, parents will need to consult with their insurance providers or consider out-of-pocket expenses, which are approximately $450 per pair. However, the inclusion of Essilor Stellest in major vision insurance plans is expected to grow in the near future, making this groundbreaking treatment more accessible.

In conclusion, the approval of Essilor Stellest lenses marks a significant step forward in myopia management, providing parents with a new tool to help mitigate the worsening of their child's vision. As the product becomes more widely available, further research and clinical trials will be essential to better understand its long-term effectiveness and broader applicability in the population.

Sources:

• Glasses That Slow Your Child’s Myopia Progression Are Now Available Following Recent FDA Approval